var data={"title":"Cytomegalovirus immune globulin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cytomegalovirus immune globulin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5969?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cytomegalovirus-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cytomegalovirus immune globulin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cytomegalovirus-immune-globulin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cytomegalovirus immune globulin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156155\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CytoGam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663230\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>CytoGam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156175\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Immune Globulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156157\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prophylaxis of CMV disease in kidney transplant:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial dose (within 72 hours of transplant): 150 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2-, 4-, 6-, and 8 weeks after transplant: 100 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12- and 16 weeks after transplant: 50 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial dose (within 72 hours of transplant): 150 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2-, 4-, 6-, and 8 weeks after transplant: 150 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12- and 16 weeks after transplant: 100 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Treatment of severe CMV pneumonitis in hematopoietic stem cell transplant (off-label use; in combination with ganciclovir):</b>  IV: 400 mg/kg on days 1, 2, and 7, followed by 200 mg/kg on day 14; if still symptomatic, may administer an additional 200 mg/kg on day 21 (Reed, 1988) <b>or</b> 150 mg/kg twice weekly (Alexander, 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670247\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cytomegalovirus-immune-globulin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cytomegalovirus immune globulin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Prophylaxis of CMV disease in kidney, liver, lung, pancreas, or heart transplant:</b> Children and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156158\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156159\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Infuse at minimum rate possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795927\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156142\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CytoGam&reg;: 50 mg (&plusmn; 10 mg)/mL (50 mL) [contains sodium 20-30 mEq/L, human albumin, and sucrose 50 mg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156128\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156145\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer through an IV line containing an in-line 15 micron filter (a 0.2 micron filter is also acceptable) using an infusion pump. The solution must be free of particulate matter and colorless. Do not mix with other infusions; do not use if turbid. Begin infusion within 6 hours of entering vial, complete infusion within 12 hours of vial entry.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Initial dose:</i> Infuse at 15 mg/kg/hour. If no adverse reactions occur within 30 minutes, may increase rate to 30 mg/kg/hour. If no adverse reactions occur within the second 30 minutes, may increase rate to 60 mg/kg/hour; maximum rate of infusion: 75 mL/hour. Monitor closely after each rate change. If patient develops nausea, back pain, or flushing during infusion, slow the rate or temporarily stop the infusion. Discontinue if blood pressure drops or in case of anaphylactic reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Subsequent doses:</i> Infuse at 15 mg/kg/hour for 15 minutes; if no adverse reactions occur, may increase rate to 30 mg/kg/hour for 15 minutes; if no adverse reactions occur, may increase rate to 60 mg/kg/hour; maximum rate of infusion: 75 mL/hour.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156143\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, and heart transplants; concomitant use with ganciclovir should be considered in organ transplants (other than kidney) from CMV seropositive donors to CMV seronegative recipients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475201\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cytomegalovirus (CMV) pneumonitis in solid organ transplant (adjunctive therapy); Cytomegalovirus (CMV) pneumonitis in hematopoietic stem cell transplant (HSCT) (adjunctive therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156182\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CytoGam may be confused with Cytoxan, Gamimune N</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156134\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;6%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle cramps</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Abdominal pain, acute renal failure, acute respiratory distress, anaphylactic shock, angioedema, anuria, apnea, aseptic meningitis, bronchospasm, bullous dermatitis, circulatory shock, coma, cyanosis, decreased blood pressure, dyspnea, epidermolysis, erythema multiforme, hemolysis, hepatic insufficiency, hypersensitivity reaction (systemic), hypotension, hypoxemia, increased blood urea nitrogen, increased serum creatinine, leukopenia, loss of consciousness, oliguria, osmotic nephrosis, pancytopenia, positive direct Coombs test, proximal tubular nephropathy, pulmonary edema, renal insufficiency, renal tubular necrosis, rigors, seizure, Stevens-Johnson syndrome, thromboembolism, transfusion-related acute lung injury, tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156147\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cytomegalovirus immune globulin (CMV-IGIV), other immunoglobulin preparations, or any component of the formulation; selective immunoglobulin A deficiency </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156132\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; monitor vital signs during infusion; discontinue immediately for hypotension or anaphylaxis; immediate treatment (including epinephrine 1 mg/mL) should be available. Systemic allergic reactions are rare; may be treated with epinephrine and diphenhydramine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg). Symptoms include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements and nausea and vomiting. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary edema: Monitor for adverse pulmonary events including transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function and  usually occurs within 1-6 hours after infusion; may be managed with oxygen and respiratory support. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment:  Acute renal dysfunction (increased serum creatinine, oliguria, osmotic nephrosis, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Patients at risk for renal failure include the elderly, patients with preexisting renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; patients at risk include those with advanced age or a history of atherosclerosis, cardiovascular and/or thrombotic risk factors, or known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypovolemia: Patients should not be volume depleted prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in patients &gt;65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Albumin: Product is stabilized with albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: Product is stabilized with sucrose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299116\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156136\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9315&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156138\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156149\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4813545\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156140\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (BUN, serum creatinine prior to initial infusion and periodically thereafter); urine output; vital signs, including blood pressure (throughout infusion); signs/symptoms of infusion-related adverse reactions, anaphylaxis; signs and symptoms of hemolytic anemia; blood viscosity (baseline; in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; weight gain, clinical response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156131\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">CMV-IGIV is a preparation of immunoglobulin G (and trace amounts of IgA and IgM) derived from pooled healthy blood donors and contains a high titer of CMV antibodies; administration provides a passive source of antibodies against cytomegalovirus to attenuate or reduce the incidence of serious CMV disease </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755632\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: 8 to 24 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323090\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (Cytogam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (50 mL): $1,542.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3462463\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cytotec (BB);</li>\n      <li>Megalotect (IL, KR, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20500045\"></a>Alexander BT, Hladnik LM, Augustin KM, et al, &ldquo;Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients,&rdquo; <i>Pharmacotherapy</i>, 2010, 30(6):554-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/20500045/pubmed\" target=\"_blank\" id=\"20500045\">20500045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humar A, and Snydman D, &ldquo;Cytomegalovirus in solid organ transplant recipients,&rdquo; <i>Am J Transplant</i>, 2009, 9(Suppl 4):578-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/20070700/pubmed\" target=\"_blank\" id=\"20070700\">20070700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23896556\"></a>Kotton CN, Kumar D, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. <i>Transplantation</i>. 2013;96(4):333-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/23896556/pubmed\" target=\"_blank\" id=\"23896556\">23896556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23465003\"></a>Razonable RR, Humar A and the AST Infectious Disease Community of Practice. Cytomegalovirus in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(Suppl 4):93-106<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/23465003/pubmed\" target=\"_blank\" id=\"23465003\">23465003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed EC, Bowden RA, Dandliker PS, et al, &ldquo;Efficacy of Cytomegalovirus Immunoglobulin in Marrow Transplant Recipients With Cytomegalovirus Pneumonia,&rdquo; <i>J Infect Dis</i>, 1987, 156(4):641-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/3040870/pubmed\" target=\"_blank\" id=\"3040870\">3040870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2847610\"></a>Reed EC, Bowden RA, Dandliker PS, et al, &ldquo;Treatment of Cytomegalovirus Pneumonia With Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients With Bone Marrow Transplants,&rdquo; <i>Ann Intern Med</i>, 1988, 109(10):783-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/2847610/pubmed\" target=\"_blank\" id=\"2847610\">2847610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Renal Insufficiency and Failure Associated With Immune Globulin Intravenous Therapy - United States, 1985-1998.&rdquo; <i>MMWR</i>, 1999, 48(24):518-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/10401909/pubmed\" target=\"_blank\" id=\"10401909\">10401909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokos DR, Berger M, and Lazarus HM, &ldquo;Intravenous Immunoglobulin: Appropriate Indications and Uses in Hematopoietic Stem Cell Transplantation,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2002, 8(3):117-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/11939601/pubmed\" target=\"_blank\" id=\"11939601\">11939601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zamora MR, Nicolls MR, Hodges TN, et al, &ldquo;Following Universal Prophylaxis With Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation,&rdquo; <i>Am J Transplant,</i> 2004, 4(10):1635-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-drug-information/abstract-text/15367218/pubmed\" target=\"_blank\" id=\"15367218\">15367218</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9315 Version 98.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156155\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663230\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156175\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156157\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F15670247\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156158\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F156159\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795927\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156142\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F156128\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F156145\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156143\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475201\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156182\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156134\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156147\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156132\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299116\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156136\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156138\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156149\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F4813545\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156140\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156131\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45755632\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323090\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F3462463\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9315|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cytomegalovirus-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">Cytomegalovirus immune globulin: Patient drug information</a></li><li><a href=\"topic.htm?path=cytomegalovirus-immune-globulin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cytomegalovirus immune globulin: Pediatric drug information</a></li></ul></div></div>","javascript":null}